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difference in complication rates between the groups
(p = 0.465) and there was no peri-operative mortality. Hos-
pital stay was shorter in the PVE group (7.84 VS 8.95 d,
p = 0.038). 5-year overall survival rate and disease free sur-
vival rate were similar between groups (53.2% VS 54.4%;
p = 0.999 and 38.3% VS 40.6%; p = 0.823) Median overall
survival and disease free survival were 65.4 months and 33.6
months respectively, with a median overall follow-up of 39.3
months.
Conclusion: Our results showed similar survival whether
PVE was used or not. Hence, PVE offers a chance for cure
for patients who could not be operated upfront. Moreover,
PVE patients seem to have the same prognosis even with a
larger extent of disease.
LO-E.09 EVALUATING ATTITUDES
TOWARD AND APPLICATION OF
MECHANISMS TO AUGMENT THE
LIVER IN NORTH AND SOUTH
AMERICA (THE MALINSA SURVEY)
R. W. Day, C. Conrad, J. Vauthey, T. A. Aloia
Department Of Surgical Oncology, The University
Of Texas MD Anderson Cancer Center, Houston,
TEXAS
Introduction: Various techniques, including PVE, PVL,
and ALPPS, are being used to augment the future liver
remnant volume in preparation for major hepatectomy. Given
the significant variation between and within these tech-
niques, there is no scientific way to compare their safety and
efficacy.
Purpose: The aim of this study was to survey and document
the availability, variation, utilization and attitudes toward
each of these techniques across high volume HPB centers in
North and South America.
Method: A descriptive 20 question survey was developed
and internally validated with expert review. The survey was
IRB approved and distributed to 42 high volume centers in
Canada, US, Mexico, and South America. Data were col-
lected, collated and analyzed.
Results: Complete surveys were returned from 23 institu-
tions, including representatives from each region (Canada,
US, Mexico, and South America). All of the institutions
responding performed PVE with 5 centers (21.7%) also per-
forming ALPPS procedures. In the previous year, the average
PVE and ALPPS procedures performed were 15.75 and 6.2
per instutition respectively. Only 18 (78.3%) reported the
capability to extend PVE to segment 4, and 12 (52.2%)
reported embolization utilizing embolic microspheres.
Twenty respondents (87%) rated PVE the safest option for
liver hypertrophy; however, 12 respondents (52.2%) believe
the ALPPS procedure is most likely to result in adequate
hypertrophy.
Conclusions: There exists extreme variability in utilization
and attitudes toward the available techniques for FLR volume
augmentation. Penetration of best practice techniques for
PVE is lacking and may contribue toward the attraction of the
riskier ALPPS procedure.
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OP-I.01 T2 GALLBLADDER CANCER –
STILL A NODAL DISEASE
M. R. Sheikh, H. Osman, S. Cheek, S. Hunter,
D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Treatment of gall bladder cancer (GBC) has
traditionally been viewed with pessimism and lymph node
positivity has been associated with worse prognosis. The aim
of this study is to analyze lymph node positivity in patients
with T2 tumors.
Methods: All patients who underwent surgery for GBC
between September 2005 and June 2014 have been identified
retrospectively in our database. Data collected included clini-
cal presentation, operative findings, and histopathological
data.
Results: Charts of 36 patients were reviewed. 26 patients
had incidental GBC diagnosis following cholecystectomy. 10
patients were T2 on initial cholecystectomy and all under-
went subsequent radical resection. 2 patients from this group
were N1 on initial cholecystectomy and 4 more patients
became N1 on second surgery. Overall 60% patients with T2
disease had node positivity. 2 patients were found to have
residual disease at the liver margin and were upgraded to T3
following resection, one of them also had N1 disease. Overall
50% patients with T2 disease had stage upgrade after radical
resection. 10 patients were diagnosed on imaging. 3 of these
patients were unresectable and 6 were either stage T3 or
higher or node positive.
Conclusions: 60% of T2 GBC were node positive in
our experience. 50% T2 patients found on initial
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cholecystectomy have stage upgrade as a result of radical
surgery. These findings support the call for radical resection
in patients with incidental diagnosis of T2 tumor on chol-
ecystectomy. This study also shows preoperative imaging
diagnosis is associated with higher stage and overall worse
prognosis.
OP-I.03 SUBTOTAL
CHOLECYSTECTOMY FOR THE
HOSTILE GALLBLADDER
M. E. Lidsky, A. W. Castleberry, A. Perez, T. N. Pappas
Department Of Surgery, Duke University Medical Center,
Durham, NC
Background: Outcomes following the inability to
safely control the cystic duct in the setting of a hostile
triangle of Calot during cholecystectomy remain unknown.
The purpose of this study was to analyze the safety
and efficacy of subtotal cholecystectomy, with specific
attention to the necessity and timing of secondary
procedures.
Methods: Medical records of 16,585 cholecystectomies
from January 2002-August 2014 were reviewed, with iden-
tification of patients managed with subtotal cholecy-
stectomy, defined as the inability to isolate and transect the
cystic duct. We investigated surgical indications,
intraoperative variables, and 30-day postoperative morta-
lity and morbidity. We also analyzed the necessity for
ERCP, percutaneous drainage procedures, and completion
cholecystectomy.
Results: 69 (0.4%) patients underwent subtotal cholecystec-
tomy, of which 57 (82.6%) were laparoscopic; 30 (43.5%)
required conversion to laparotomy. 1 (1.4%) patient died
postoperatively, and 26 (37.7%) patients suffered 35 compli-
cations, most frequently infectious (14 wound/surgical site
infections, 4 UTIs). Indication for cholecystectomy included
acute cholecystitis (69.6%), 10 (14.5%) of which had a
cholecystostomy tube, symptomatic cholelithiasis (23.2%),
chronic cholecystitis (13%), and biliary pancreatitis (10.1%).
Secondary interventions were required in the form of 49
ERCPs in 20 (29%) patients, percutaneous drainage for
biloma or abscess in 6 (8.7%), and completion cholecystec-
tomy on average 13.75 months (5–27 months) after the index
operation in 4 (5.8%).
Conclusions: The hostile gallbladder represents a com-
plicated disease process for which patient safety is
of paramount. Postoperative morbidity after subtotal
cholecystectomy is significant. Most do not require
completion cholecystectomy; however, these patients
demand close observation and, frequently, secondary
interventions.
OP-I.04 MAJOR BILE DUCT INJURY
AFTER LAPAROSCOPIC
CHOLECYSTECTOMY: EXPERIENCE
FROM A TERTIARY REFERRAL CENTER
IN A RURAL STATE
A. Greenbaum, E. Alkhalili, I. Nir
University Of New Mexico, Albuquerque, NEW MEXICO
Background: Risk factors for iatrogenic bile duct injuries
(BDI) after laparoscopic cholecystectomy (LC) remain a
topic of controversy. Few studies have examined ethnicity or
body mass index as potential risk factors resulting in the need
for complex biliary reconstruction. We hypothesize that LC
performed in a rural setting may present a higher risk of BDI
in certain patient populations.
Methods: This retrospective cohort study includes all
patients referred to our tertiary center from 2010–2014
for biliary reconstruction secondary to major BDI during
LC.
Results: A total of 21 patients were analyzed. These patients
were predominately female (76% vs. 24% male). A dispro-
portionate number of patients were Native American (47.6%
vs. 10.4% comprising the New Mexico state population). The
mean BMI of all patients was 33.5, though the Native Ameri-
can population average BMI was 39.2. The majority of refer-
rals came from rural centers (62%). The mean time to BDI
recognition after LC was highest at rural facilities (16.4 days
vs. 3.3 days at metropolitan centers) as well as the timing
of referral (4.7 days vs. 0.8 days). The overall rate of mor-
bidity was 42.8% and one patient died of sepsis prior to
reconstruction.
Conclusion: Major BDI after LC is a highly morbid event.
This retrospective cohort study suggests Native American
patients, specifically those who are morbidly obese, may be
at higher risk of BDI during laparoscopic cholecystectomy in
a rural setting. We prompt rural surgeons to consider early
referral of high risk patients to a tertiary setting for gallblad-
der surgery.
OP-I.05 RACIAL DISPARITIES IN
PATIENTS WITH GALLBLADDER
CANCER
S. Zenoni1, X. Zhu1, P. Velduis1, S. Eubanks1,2,
P. Arnoletti1,2, S. De La Fuente1,2
1Florida Hospital Orlando, Orlando, FL; 2University Of
Central Florida, Orlando, FL
Background: Epidemiological studies have shown widely
variable geographic patterns in patients with gallbladder
cancer. The incidence rates are extraordinarily high in Latin
America, Asia and some countries in eastern and central
Europe but relatively low in the United States. In contrast to
other biliary malignancies, there is limited data regarding
racial disparities and oncologic outcomes in patients with
gallbladder cancer. In this study, a prospectively maintained
tumor registry was used to determine overall survival, time-
to-initial treatment, and time-to-surgery according to race in
patients with gallbladder cancer.
Methods: Patients with gallbladder cancer registered at the
Florida Hospital tumor database from the year 2001–2013
were included in the analysis. Analyzed variables included
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basic demographics as well as grade and pathological ACCJ
stage at diagnosis, date at diagnosis, initial treatment date,
surgery date, last date of contact, patient’s status (alive/dead)
at the last contact, and overall survival according to race.
Results: A total 133 patients with gallbladder cancer were
identified from the database; 91 of which were identified as
non-Hispanic, 22 as Hispanics, and 20 as African Americans.
There were no differences in age, gender distribution, grade
and pathological ACCJ stage at presentations between the
different races. Five-years overall survival (figure), time-to-
initial treatment, and time-to-surgery were not significantly
different between groups.
Conclusions: This study shows similar survival rates and
time to therapy between Caucasian and minorities. Further-
more, as opposed to what it has been observed with other
cancers, no differences were noted in time-to-treatment in
gallbladder cancer according to race.
OP-I.06 THE IMPACT OF CONCOMITANT
BILE DUCT RESECTION WITH MAJOR
HEPATECTOMY ON SURVIVAL
OUTCOMES OF PATIENTS
UNDERGOING TREATMENT OF
METASTATIC COLORECTAL CANCER:
A MULTI-INSTITUTIONAL ANALYSIS
OF 429 PATIENTS
L. M. Postlewait1, M. H. Squires1, D. A. Kooby1,
S. M. Weber2, C. R. Scoggins3, K. Cardona1, C. S. Cho2,
R. C. Martin3, E. Winslow2, S. K. Maithel1
1Division Of Surgical Oncology, Emory University, Atlanta,
GA; 2Division Of Surgical Oncology, University Of
Wisconsin, Madison, WI; 3Division Of Surgical Oncology,
University Of Louisville, Louisville, KY
Background: Data are lacking on the long-term outcomes
of patients undergoing major hepatectomy requiring a bile
duct resection for the treatment of colorectal cancer
metastases.
Methods: All patients who underwent major hepate-
ctomy (≥3 segments) for metastatic colorectal cancer from
2000 to 2010 at three US academic institutions were
included. Patients who died from unknown cause were
excluded. Primary outcome was disease-specific survival
(DSS).
Results: Of 456 patients, 429 met inclusion criteria.
Median follow-up was 38.7 mos. Bile duct resection was
performed in 9 patients (2.1%) and was associated with pre-
operative portal vein embolization (25.0%vs4.3%;p =
0.049). There were no significant differences in other clin-
icopathologic factors between the two groups (age, ASA
class, margin status, number of lesions, tumor size, cirrhosis,
perineural invasion, and lymphovascular invasion). Bile
duct resection was associated with increased postope-
rative major complications (Clavien III-V) in univariate
(66.7%vs20.7%;p = 0.004) and multivariate analyses (HR:
6.22;95%CI: 1.44–26.97;p = 0.015). There were no differ-
ences in length of stay, reoperation, readmission, or 30-day
mortality rates. Patients who underwent bile duct resection
had shorter DSS compared with patients not requiring bile
duct resection (9.3 vs 39.9 mo; p = 0.002; Figure). When
accounting for differences between the two groups, the need
for bile duct resection was independently associated with
reduced DSS (HR: 3.06;95%CI: 1.12–8.34;p = 0.029).
Conclusion: Major hepatectomy with concomitant bile duct
resection is seldom performed in patients undergoing resec-
tion of colorectal cancer liver metastases. Bile duct resection
is associated with higher major morbidity and reduced
disease-specific survival. Stringent selection criteria should
be applied when patients may need bile duct resection during
hepatectomy for colorectal cancer liver metastases.
OP-I.08 INCORPORATING TRANSITION
TO PRACTICE INTO A
HEPATOPANCREATICOBILIARY
FELLOWSHIP: A MODEL FOR
GRADUATED AUTONOMY
C. Scally, S. G. Warner, R. M. Minter
University Of Michigan, Ann Arbor, MICHIGAN
Introduction: There is significant concern for graduating
trainees’ readiness for independent practice. The American
College of Surgeons (ACS) has developed pilot fellowships
to facilitate “Transition to Practice.” However, these pro-
grams currently serve as an alternative to advanced
subspecialty training. We sought to evaluate our institutional
experience incorporating a novel transition to practice
element into an advanced HPB fellowship.
Methods: We obtained complete operative records from
Fiscal Years 2012–14 through present for our HPB fellows
(2011–13 fellow A, 2013–15 fellow B). We then identified all
cases in which the fellows billed as the attending surgeon, as
well as all cases in which they participated as a trainee. We
also analyzed relative value units (RVUs), and total charges
billed by the fellows per financial year.
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Results: The independent practice element expanded in
each year of the fellowship (Table). Independent cases rep-
resented 36.6% of the fellows’ total operative volume from
2012–14. In the second year of the fellowship, the fellows
have increased the complexity of diagnoses seen in their
personal clinic with explicit recognition of their ability to
progress in this manner. The fellows do not participate in
either emergency or service call as an attending.
Conclusions: Our HPB fellows’ training included a signifi-
cant independent practice component, with an expanding
scope of practice in each year of training. This method of
graduated autonomy in an advanced HPB fellowship may
represent a feasible blended model for advanced surgical
training, meeting both the need for specialty expertise and
preparation for independent practice.
OP-I.09 STROKE VOLUME VARIATION
(SVV) CONTINUOUS MONITORING FOR
INTRAOPERATIVE INTRAVASCULAR
FLUID MONITORING IN HPB SURGERY
E. H. Baker, J. Drummond, A. Cochran, R. Seshadri,
J. Martinie, D. Iannitti, R. Swan
Carolinas HealthCare System, Charlotte, NORTH
CAROLINA
Introduction: Previous studies have demonstrated that
stroke volume variation (SVV) represents a more accurate
determinant of intravascular volume status and fluid respon-
siveness. This has been particularly true for patients who are
intubated in which previously used measurements of intra-
vascular status such as mean arterial pressure (MAP) or
central venous pressure (CVP) may be misrepresentative.
Methods: Continuous intraoperative monitoring was per-
formed for a consecutive series of patients who underwent
laparoscopic and open liver and pancreas surgeries. Data
points collected for analysis included SVV, MAP, CVP,
stroke volume (SV), cardiac index (CI) every 5 minutes.
Estimated blood loss (EBL), hemoglobin (Hgb), pH and
surgeon and anesthesia estimates of patient volume status
were determined every hour.
Results: 23 patients were enrolled and underwent continu-
ous monitoring during the following procedures: 5 open
liver, 6 laparoscopic liver, 6 open pancreas, 6 laparoscopic
pancreas. A weak inverse relationship was seen between
SVV and total fluid status in 14 out of 23 total cases (60.9%)
as indicated by a negative linear regression slope. The cor-
relations were low for all groups, with an average R2 of 0.10
– or 10% of the variability in the model explained by the
SVV and total fluid variables.
Conclusions: SVV correlates inversely with total fluid
status and may be a used as a non-invasive tool in determin-
ing fluid status in HPB procedures. While the sample size
was small, we plan on using the data to develop a standard-
ized fluid management protocol for HPB surgeries and
examine surgical outcomes compared to matched, retrospec-
tive cases.
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OP-I.10 RECURRENCE PATTERN AND
SURVIVAL IN PATIENTS UNDERGOING
SIMULTANEOUS RESECTION FOR
SYNCHRONOUS LIVER METASTASES
FROM PRIMARY COLORECTAL
CANCER : RETROSPECTIVE STUDY OF
286 PATIENTS FROM A SINGLE HIGH
VOLUME HPB CENTRE
R. Kumar1, S. Park2
1Sir H.N. Reliance Foundation Hospital, Mumbai,
MAHARASHTRA; 2National Cancer Center, Goyang,
GYEONGGI-DO
Background: The optimal combination of available thera-
pies for patients with resectable synchronous liver metastases
from colorectal cancer (SLMCC) is unknown, and the pattern
of recurrence after simultaneous resection has been poorly
investigated. In this study, the authors examined recurrence
patterns and survival after simultaneous resection for
SLMCC.
Methods: Consecutive patients with SLMRC who under-
went complete simultaneous resection of both the rectal
primary and liver metastases with curative intend between
May 2001 and December 2010 were identified from a pro-
spective database. Fifteen patients were excluded due to
follow-up loss. Clinicopathological factors were retrospec-
tively analyzed to investigate initial recurrence pattern affect-
ing survival.
Results: In total, 286 patients underwent simultaneous
resection of both primary colorectal cancer and liver metas-
tases with curative intend. The 3, 5 and 10-years recurrence-
free survival rate were 35.5%, 31.5% and 27.2%,
respectively, for the entire cohort with a median follow-up of
60.8 months for survivors. 196 patients(68.5%) developed a
recurrence. Most common site of the initial recurrence was
liver(48.5%), followed by the lung (25%). Initial recurrence
pattern correlated with survival (P < 0.001). Analysis dem-
onstrated that a loco-regional recurrence was significant risk
factor for survival.
Conclusions: Of the patients with SLMCC who developed
recurrent disease, systemic sites were overwhelmingly more
common than pelvic recurrences. The current results indi-
cated that initial recurrence patterns in patients undergoing
simultaneous resection with curative intent was important to
predict survival, especially in patients with loco-regional
recurrence. Also, simultaneous resection seems safe and fea-
sible despite lack of evidence, provided an institution specific
protocol is followed.
OP-I.11 IS THERE A ROLE FOR NEAR
INFRARED SPECTOMETRY (NIRS)
OXYMETRY DURING LIVER SURGERY?
Y. Collin1, T. Hu1, R. Allard1, A. Cloutier1, F. Payette1,
A. Denault2,3, R. Lapointe1, F. Vandenbroucke-Menu1
1Centre Hospitalier Universitaire de Montreal, Service de
Chirurgie HBP, Montreal, QC; 2Centre Hospitalier
Universitaire De Montreal, Soins Intensifs, Montreal, QC;
3Institut De Cardiologie De Montreal, Soins Intensifs,
Montreal, QC
Introduction: Peri-operative cerebral and somatic oxy-
metry is used for monitoring during cardiac surgery, but it
has never been used in liver surgery. Our goal was to define
the place of NIRS oxymetry in liver resections.
Methods: 90 patients undergoing major hepatectomy were
included (45 men and 45 women). Oxymetry was obtained
by NIRS at 4 sites (cerebral right and left, arm and thigh)
before and during surgery. Baseline oxymetry (BaseO) and
desaturation (Desat) (Threshold = 80% baseline) values
were compared to peri-operative data.
Results: Median ICU stay was 2d and median hospital stay
(LOS) was 7d. Cerebral BaseO correlated significantly with
duration of stay in the intensive care unit (ICU) stay
(p = 0.04), in the hospital length of stay (LOS) (p = 0.01) and
respiratory insufficiency (p = 0.002). Arm BaseO correlated
with blood loss (p = 0.05), blood transfusion (p = 0.03), ICU
stay (p = 0.01) and surgical complications (p = 0.049). Also,
thigh BaseO correlated with surgical complications
(p = 0.0035) and LOS (p = 0.01). Cerebral Desat did not
correlate with any complication but thigh Desat did with
blood loss (p = 0.03), LOS (p = 0.05) and surgical complica-
tions (0.0132). Arm Desat inversely correlated with Pringle
duration (p = 0.01).
Conclusion: NIRS is a very simple approach for oxymetry
evaluation during major liver surgery. Baseline and systemic
values are correlated with some operative data and compli-
cations. These preliminary results should lead to a more
extensive study to determine whether correction of impaired
level of oxymetry will improve patients’ outcome.
OP-I.12 USING THE CLINICAL RISK
SCORE TO PREDICT WHICH PATIENTS
WILL BENEFIT FROM PRE-OPERATIVE
CHEMOTHERAPY FOR COLORECTAL
LIVER METASTASES
N. Sela1,2, K. A. Bertens1,2, S. Welch1,2, J. Chung2,
C. S. Yoshy1, R. Hernandez-Alejandro1,2
1London Health Sciences Centre, London, ONTARIO;
2Western University, London, ONTARIO
Background: Pre-operative chemotherapy has become a
mainstay in the treatment of colorectal liver metastases
(CRLM) in patients with both resectable and unresectable
disease. We aim to evaluate whether the Clinical Risk Score
(CRS) can be used to predict patients with resectable disease
who will benefit from metastectomy before chemotherapy.
Methods: All patients with CRLM who underwent 4 or
more cycles of chemotherapy at our institution between 2000
and 2013 were retrospectively analyzed. Patients had to have
cross-sectional computed tomography (CT) imaging before
and after the treatment to meet inclusion criteria. Tumor
response was determined using RECIST 1.1 criteria. The
primary outcome was tumor progression, defined as RECIST
1.1 progressive disease. No progression was defined as
RECIST 1.1 stable disease, complete response, or partial
response. Multivariate regression was used to assess if the
CRS, as well as its individual components, were predictive of
disease progression.
Results: Seventy-seven patients were identified (mean
follow-up of 2.19 ± 1.50 years). Twenty-seven patients had
progressive disease (35.1%). On multivariate analysis, a
lower CRS was predictive of disease progression on chemo-
therapy (OR = 0.370, p = 0.018). Furthermore, patients with
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5 or more metastases (OR 0.122, p = 0.023), and increased
size of the largest lesion (OR 0.647, p = 0.047) were less
likely to progress.
Conclusion: Patients with more aggressive tumors, as
reflected by a higher CRS, are less likely to have tumor
progression on chemotherapy. Conversely, patients with low
CRS are more likely to progress on chemotherapy, and there-
fore those with resectable disease upfront would benefit from
metastectomy (without pre-operative chemotherapy).
OP-I.13 INTRAOPERATIVE
RADIOFREQUENCY ABLATION VERSUS
SURGICAL RESECTION IN SOLITARY
SMALL HCC
A. M. Elgendi, M. Elshafey, E. Bdeawey
Faculty Of Medicine, Alexandria University,
ALEXANDRIA, SELECT A STATE/PROVINCE
Background: Percutaneous radiofrequency ablation (RFA)
is used for treatment of small HCC however surgeons are
frequently using intraoperative RFA for tumors at locations
difficult for the percutaneous procedure. The aim was to
evaluate the results of intraoperative RFA for small HCCs
(<2 cm) at locations difficult for percutaneous route.
Methods: 420 patients with small solitary HCC (<2 cm)
were treated; 328 via percutaneous RFA while 92 patients
presented at sites not amenable for percutaneous route. 48
out of 92 patients underwent surgical resection, while 44/92
patients underwent intraoperative RFA.
Results: The location and depth of the HCC from the liver
capsule was the only significant factors in the choice of the
surgeon between resection and RFA. RFA group acheived
complete ablation rate of 100% compared to the surgery
group, where all patients achieved R0 resection. Complica-
tion rate was comparable (p = 1.0). After a median follow-up
of 46 months (range, 16–65 months), no tumors showed
neither local progression nor local recurrence and no signifi-
cant difference was observed between two groups as regards
early recurrence and number of de novo lesions (p = 0.49).
One-year and 3-year survival rates were 92% and 83%,
respectively, in the resection group comparable to the corre-
sponding rates of 91% and 76% in the RFA group (p = 0.8).
Conclusion: For small HCC in locations difficult for a per-
cutaneous approach, intraoperative RFA can be an alternative
option for deep seated tumors necessitating more than one
segmentectomy achieving similar tumor control, overall and
disease-free survival.
OP-I.14 HEALTH-RELATED QUALITY OF
LIFE FOLLOWING TREATMENT OF
NEUROENDOCRINE LIVER METASTASIS
G. Spolverato, H. Maqsood, Y. Kim, T. Luo, R. Gupta,
T. M. Pawlik
Johns Hopkins Hospital, Baltimore, MARYLAND
Background: A large subset of patients with neuro-
endocrine liver metastasis(NELM) is symptomatic at the
time of presentation. In addition to improving survival, treat-
ment of NELM seeks to provide palliation of symptoms.
Data on health-related quality of life(QoL) are uncommon.
We sought to define patient-reported QoL following treat-
ment of NELM.
Methods: Patients who underwent treatment of NELM at
Johns Hopkins Hospital between 1998–2013 and who were
alive as of March 2014 were identified(n = 276). These
patients were invited to complete a QOL survey designed
using validated assessment tools.
Results: The response rate was 27.5%(n = 76); question-
naires were completed at a median of 49.1 months(range,
23.3–117.8) following initial treatment. Median patient age
was 55 years and the majority was male(n = 43, 56.6%).
Most patients had a pancreatic(n = 21, 27.6%) or a small
bowel(n = 30, 39.5%) primary tumor; the overwhelming
majority had multiple NELM(88.2%). Prior to the initiation
of any therapy, 84.2% patients reported symptoms, with the
most common symptoms being fatigue(78.9%), diar-
rhea(67.1%), and flushing(44.7%). Initial treatment of
NELM consisted of resection ± ablation(64.5%) or intra-
arterial therapy(IAT)(35.5%). Many patients reported overall
improvement in physical health(41.4%) and mental
health(34.3%). After treatment, the proportion of patients
with severe symptoms decreased from 36.8% to
21.0%(P = 0.03); symptoms such as diarrhea and flushing
improved at the end of the treatment course(both p < 0.05),
whereas fatigue remained unchanged(p = 0.45).
Conclusions: Surgery and IAT management of NELM
provides a reasonable improvement in patient-reported
symptoms and QoL. Liver-directed therapies should be con-
sidered in those patients with symptomatic, high-volume
disease even if complete treatment of the NELM is not
feasible.
OP-I.15 IMAGING SURVEILLANCE OF
HEPATOCELLULAR ADENOMAS
Y. Chun, R. Parker, S. Reddy, E. Ehrenwald, M. Hill,
S. Inampudi, T. Sielaff
Virginia Piper Cancer Institute, Minneapolis, MN
Background: A consensus surveillance protocol is lacking
for patients with hepatocellular adenomas.
Methods: Patients with hypervascular hepatic lesions
≤5 cm that did not meet criteria for focal nodular hyperplasia
or hepatocellular carcinoma were entered into a surveillance
schedule with contrast-enhanced MRI 6, 12, and 24 months
after baseline imaging. Patients with risk factors, including
male gender and active oral contraceptive pill (OCP) use,
were excluded. If lesions remained stable or decreased in
size, then surveillance imaging was discontinued.
Results: Between 2011–2014, 109 consecutive patients with
benign hypervascular lesions were evaluated at our multidis-
ciplinary liver conference. Median follow-up from date of
diagnosis was 24 months (range, 0–168 months). By imaging
criteria or biopsy, 37 patients were diagnosed with focal
nodular hyperplasia, and 44 patients with hepatocellular
adenoma, including 18 with adenomatosis. Twenty-eight
patients had indeterminate lesions. Clinically significant
hemorrhage +/− rupture occurred in 6 patients without prior
imaging and 2 patients with known hypervascular hepatic
lesions. All patients who suffered hemorrhage had adenomas
>5 cm and other risk factors, including OCP use (n = 7) and
anticoagulation (n = 1). In 43 patients eligible for our
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surveillance schedule, all lesions remained stable or
decreased in size, and no patient developed complications.
Conclusions: Patients with hepatocellular adenomas
without risk factors, such as size >5 cm or OCP use, can
safely be observed with serial imaging 6, 12, and 24 months
after initial diagnosis. If lesions remain stable or decrease in
size, then longer-term surveillance is unlikely to identify
patients at risk for complications.
OP-I.17 NATIONAL TRENDS WITH
LAPAROSCOPIC LIVER RESECTION:
RESULTS FROM A POPULATION-BASED
ANALYSIS
J. He, N. Amini, G. Spolverato, K. Hirose, M. A. Makary,
C. L. Wolfgang, M. J. Weiss, T. M. Pawlik
The Johns Hopkins Hospital, Baltimore, MD
Background: Interest in laparoscopic liver resection (LLR)
has grown since the International “Louisville Statement” was
published in 2009. However, limited population-based data on
LLR utilization patterns and outcomes are available.
Methods: LLR data from the Nationwide Inpatient Sample
(NIS, 2000–2012) and the National Surgical Quality
Improvement Project (NSQIP, 2005–2012) were divided into
2 cohorts, before and after the Louisville Statement. Patient
demographics, indications, trends in LLR utilization, and
perioperative outcomes were compared before and after the
2009.
Results: Patients undergoing open versus LLR were com-
parable with regard to age, sex, and comorbidity status
(Table). 1,131 and 642 LLR were identified from NIS and
NSQIP, respectively. The majority of patients underwent
LLR for a malignant indication (NIS: primary malignancy,
29.9% vs. metastasis, 43.2%; NSQIP: primary malignancy,
25.7% vs. metastasis, 42.2%). The mean annual volume of
LLR increased from 2000–2008 vs. 2009–2012 (NIS: 63 vs.
168; NSQIP: 52 vs. 127; both P < 0.01). The perioperative
mortality associated with LLR was low (NIS: 2.8% vs.
NSQIP: 0.9%), while the morbidity was higher (NIS: 38.1%
vs. NSQIP: 30.7%); mortality and morbidity did not change
over time (both P > 0.05). Since 2009, LLR was associated
with a shorter length of stay (NIS: 5 vs. 6 days, P < 0.01) and
more likely to be performed in teaching hospitals (NIS: 93%
vs. 87%, P = 0.02).
Conclusions: Since the Louisville Statement in 2009, utili-
zation of LLR has increased. LLR appears to be safe with
low mortality and reasonable morbidity, as well as be asso-
ciated with a modest decrease in LOS.
OP-I.18 POST-HEPATECTOMY
HYPERBILIRUBINEMIA: THE POINT
OF NO RETURN
J. Y. Liu1, L. M. Postlewait1, J. W. Etra1, M. H. Squires1,
K. Cardona1, J. H. Winer1, J. M. Sarmiento2, C. A. Staley 1,
S. K. Maithel1, D. A. Kooby1, M. C. Russell1
1Emory Winship Cancer Institute, Atlanta, GA; 2Emory
Department Of Surgery, Atlanta, GA
Background: Post-hepatectomy hyperbilirubinemia is asso-
ciated with liver insufficiency and failure. The threshold of
the highest survivable total bilirubin (tbili) is not defined. Our
aim was to identify the peak postoperative tbili beyond which
is survival is improbable.
Methods: An institutional database of patients undergoing
major hepatectomy (≥3 segments), excluding biliary resec-
tions, from 2000–2012 was reviewed. A peak bilirubin of
≥18 mg/dL in the first 45 days post op was associated with
increasing 90-day mortality (90DM). Clinicopathologic
factors were assessed for association with 90DM. We also
examined predictors of elevated postoperative tbili.
Results: 607 patients were identified with a 90DM of 4.4%.
90DM for a peak tbili ≥18 (n = 16) was 81%, compared to
2.4% for a bilirubin <18 mg/dL (graph). All patients with a
tbili ≥30 died (n = 7). On multivariate analysis (MVA) for
90DM, post-operative tbili ≥18 (HR 24, CI 3.3–174;p =
0.002), post-operative FFP (HR 4.8, CI 1.1–20.2;p = 0.034),
and cirrhosis (HR 5.9, CI 1.1–31.3;p = 0.038) were signifi-
cant predictors. Furthermore, predictors of tbili ≥18 identi-
fied on MVA included: older age (HR 1.1, CI 1.0–1.2;
p = 0.001) and postoperative FFP (HR 10.1, CI 2.5–40.8;
p = 0.001).
Conclusion: Total bilirubin ≥18 is significantly associated
with an increase in 90-day mortality after major hepatec-
tomy; there are no survivors for patients whose tbili rises
≥30.This information can help clinicians advise patients
and families who experience posthepatectomy hyperbiliru-
binemia; as well, it may be an important marker for interven-
tion as supportive therapies improve.
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OP-I.19 EARLY AND LONG-TERM
SURVIVAL OUTCOMES OF PATIENTS
WITH COLORECTAL LIVER
METASTASES RESECTED AFTER
CONVERSION CHEMOTHERAPY
M. C. Marques, H. S. Ribeiro, R. S. De Souza,
W. L. Da Costa, A. L. Diniz, A. L. De Godoy,
I. C. De Farias, C. A. De Mello, F. A. Soares,
M. A. Almeida, F. J. Coimbra
A.C. Camargo Cancer Center, Sao Paulo, Brasil
Liver resection is the standard of care for patients with
colorectal liver metastases, but only 15% to 25% are
resectable at the initial diagnosis. Improvements in chemo-
therapy response rates and surgical technique expanded the
resectability criteria for patients initially considered as
having unresectable disease. These patients have an inter-
mediate prognosis between those who were upfront
resectable and those who did not achieve resectability. The
aim of this study was to analyze survival outcomes and
determine clinicopathological prognostic factors in this sce-
nario. Patients who underwent liver resection for colorectal
liver metastases after conversion therapy between 1998 and
2013 were retrospectively analyzed. Unresectability was
defined according to the Consensus Guidelines recently pub-
lished. In the study period, 352 liver resections for colorectal
metastases were performed in 268 patients. Fifty-one
patients met the inclusion criteria and were analyzed. Thirty
and 90-day mortality rate was 5.8% and 9.8%. Major mor-
bidity rate was 29.4% according to Clavien-Dindo Classifi-
cation. Median number of chemotherapy cycles before
hepatectomy was 12. With a median follow-up of 36 months,
the 3-year overall survival was 66.1% versus 76.4% in the
resectable group (p = 0.060) and 3-year disease-free survival
was 10.4% versus 35.8% (p < 0.001). In multivariate analy-
ses, factors that influenced overall survival were the occur-
rence of Class III and IV postoperative complications and
more than 4 liver nodules. There was no independent predic-
tor of disease free survival on multivariate analyses. Liver
resection after conversion therapy for colorectal liver metas-
tases is a procedure with high morbimortality but also asso-
ciated with long-term survival in selected patients.
OP-I.20 RESECTED INTRAHEPATIC
CHOLANGIOCARCINOMA: PATTERNS
OF ADJUVANT THERAPY
AND RECURRENCE
I. T. Konstantinidis 1,2, A. X. Zhu1, L. Goyal 1, D. T. Ting 1,
V. Deshpande 1, K. K. Tanabe 1, K. D. Lillemoe 1,
C. R. Ferrone 1
1Massachusetts General Hospital Department Of Surgery,
Boston, MA; 2University Of Arizona Department Of
Surgery, Tucson, AZ
Background: The majority of patients who undergo liver
resection for intrahepatic cholangiocarcinoma (ICC) suffer
from recurrence and succumb to their disease. The role of
adjuvant treatment remains unknown.
Methods: Clinicopathologic data of resected ICC between
1/2000–12/2013 were evaluated. Patterns of adjuvant therapy
and recurrence were analyzed.
Results: Of the 76 patients who underwent resection of a
ICC the median age was 65 years and 54% were female. The
majority of patients (72%) underwent a major hepatectomy
Abstracts 27
© 2015 The Authors
HPB © 2015 Americas Hepato-Pancreato-Biliary AssociationHPB 2015, 17 (Suppl. 1), 1–80
with 87% being an R0 resection. Median ICC size was
5.5 cm. Excluding patients who died within 60 days or were
lost to follow-up, 44%(30/68) did not receive adjuvant treat-
ment (median overall survival (OS)not reached), 34%(23/68)
received adjuvant therapy within 3 months (OS: 48 months),
and an additional 22%(15/68) received therapy after the first
recurrence (OS: 44 months). Adjuvant chemotherapy was
more likely to be given to patients with an R1 resection
(26%vs7%;p = 0.05) and nodal disease (35%vs11%;p =
0.02). Gemcitabine based regimens were the most common
first line (85%) (gemcitabine: 32%, gemcitabine/cisplatin:
36%, gemcitabine/oxaliplatin: 32%); 5 FU/chemoradiation
was first line in 15%. After median follow-up of 25 months
41% remained free of disease(NED), 12% had a single liver
recurrence, 13% multinodular liver recurrence and 34% ext-
rahepatic recurrence. Of the patients who recurred single
liver recurrences had the best median survival compared to
multinodular recurrences and distant disease (73 vs 23 vs 37
months respectively;p = 0.09).
Conclusions: The majority of patients undergoing resection
for an ICC either do not receive adjuvant treatment or they
receive it after recurrence of their tumor. Single nodule
hepatic recurrences have the best outcome.
OP-I.21 ROLE OF LIVER RESECTION OR
ABLATION IN METASTATIC
MELANOMA MANAGEMENT
A. Doussot1, C. Nardin1, H. Takaki2, T. Litchman2,
M. I. D’Angelica1, W. R. Jarnagin1, M. A. Postow3,
J. P. Erinjeri2, P. Kingham1
1Department Of Surgery Memorial Sloan Kettering Cancer
Center, New York, NY; 2Department Of Interventional
Radiology Memorial Sloan Kettering Cancer Center, New
York, NY; 3Department Of Medical Oncology Memorial
Sloan Kettering Cancer Center, New York, NY
Introduction: The median survival for patients with meta-
static melanoma is usually limited to approximately one year.
Liver ablation and metastasectomy are associated with
improved survival in well-selected patients, but their role in
era of more effective systemic therapies is uncertain.
Methods: Patients undergoing liver ablation or resection for
melanoma liver metastases between 1993 and 2013 were
included. Outcomes and prognostic factors such as medical
therapy impact were evaluated.
Results: Forty eight patients underwent ablation (n = 16) or
resection (n = 32) for metastases from cutaneous (n = 26) or
ocular (n = 22) origin. Median overall survival (OS) was 26
months, with 12 patients (27.3%) alive at 3 years, after resec-
tion (n = 9) and after ablation (n = 3) respectively. Patients in
the ablation group harbored more aggressive disease at time of
presentation, with more extrahepatic disease (EHD)
(p = 0.008) and a shorter disease-free interval between
primary tumor and liver metastasis diagnosis (p = 0.01). In
addition, 68.8% of patients received preoperative systemic
therapy before ablation. Median OS in ablation (18 months)
and resection (27 months) groups was not different (p = 0.9).
EHD was a poor prognostic factor for OS in the resection
group (p < 0.05; see Figure). In patients with EHD, 78% of
patients receiving preoperative therapy before ablation
experienced partial response and tended to have longer OS (12
months) compared to resected patients (6 months, p = 0.2).
Conclusion: Liver resection should be considered only in
selected patients with melanoma liver metastases without
EHD which is associated with poor outcomes. When EHD is
controlled with systemic therapy, indication for combined
liver ablation needs further investigations.
OP-I.22 RADIOFREQUENCY-ASSISTED
LIVER PARTITION AND PORTAL VEIN
LIGATION (RALPP): COMPARATIVE
SERIES OF A MODIFIED ALPPS
TECHNIQUE FOR TWO-STAGE
LIVER RESECTION
M. H. Sodergren, T. M. Gall, M. Nagendran, L. R. Jiao
Imperial College, London, GREATER LONDON
Background: The introduction of portal vein embolization
and recently the ALPPS technique has rendered a greater
proportion of liver tumours surgically resectable by increas-
ing the volume of future liver remnant (FLR) in selected
patients. The RALPP technique involves a laparoscopic first
stage portal vein ligation and in situ liver splitting using
ablation only without complete transection. We hypothesise
that this will rapidly increase the size of the FLR limiting any
associated morbidity from liver transection.
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Methods: Consecutive patients who underwent RALPP
were compared to an age-sex- and liver function-matched
cohort of patients undergoing PVE prior to right hepatec-
tomy. The primary endpoint was the percentage increase in
FLR volume. Secondary endpoints were morbidity, mortal-
ity, and postoperative liver function.
Results: There were 12 patients (6M : 6F) in the RALPP
group and 8 (4M : 4F) in the PVE group with a median age
of 62.5 and 65 yrs respectively. The mean % increase in the
FLR volume was 61.5 +/− 16.3 measured after a mean of
20.8 +/− 7.3 days following the first stage for RALPP com-
pared to a % increase of 16.46 +/− 11.7 (p = 0.001) after
52.3 +/− 14.8 days (p < 0.001) following PVE. There was
one mortality in the RALPP group at day 19 following right
hepatectomy from bowel ischaemia and liver failure. There
was no difference in morbidity or post-operative liver
function.
Conclusion: The RALPP technique is feasible and safe in
this limited series, with a greater increase in FLR volume in
a shorter time period compared to PVE.
OP-I.23 TEMPORAL TRENDS IN
SURGICAL RESECTION AND
PERI-OPERATIVE CHEMOTHERAPY
FOR COLORECTAL CANCER LIVER
METASTASES (CRCLM) IN ROUTINE
CLINICAL PRACTICE
S. Nanji1,2, W. J. Mackillop2,3,4, X. Wei3, C. M. Booth2,3,4
1Department Of Surgery, Queen’s University, Kingston,
ON; 2Department Of Oncology, Queen’s University,
Kingston, ON; 3Department Of Public Health Sciences,
Queen’s University, Kingston, ON; 4Division Of Cancer
Care And Epidemiology, Queens University Cancer
Research Institute, Kingston, ON
Background: The treatment of CRCLM continues to
change over time. We report trends in management and
outcome of all patients with resected CRCLM in Ontario,
Canada.
Methods: All cases of CRC in Ontario who underwent
surgical resection of liver metastases in 2002–2009 were
identified using the population-based Ontario Cancer Reg-
istry. Electronic records of treatment and pathology reports
were linked to the registry to identify utilization
of neoadjuvant (NACT) and adjuvant chemotherapy (ACT)
and describe surgical management and pathologic findings.
We describe differences over 2 study periods: 2002–2005
and 2006–2009.
Results: During 2002–2009, 1711 patients underwent resec-
tion of CRCLM. Mean age was 63 years. During the study
period there was a 60% increase in patients undergoing
resection of CRCLM. For the 2 study periods, mean number
of liver lesions resected was 2.0 and 2.2 (p = 0.051), mean
size of largest lesion was 4.5 cm and 4.0 cm (p = 0.003),
major hepatic resection (≥3 Couinaud segments) rate was
66% and 63% (p = 0.264) and R1 resection margin rate was
6% and 9% (p = 0.021), respectively. 90-day mortality rates
for the study periods were 4% and 3% (p = 0.499). Use of
NACT and ACT increased from 19% to 41% (p < 0.001) and
42% to 50% (p < 0.001) between study periods, respectively.
Five year overall survival during the 2 study periods was 43%
(95%CI 40–47) and 45% (95%CI 42–48) (p = 0.402).
Conclusions: Resection of CRCLM and the use of peri-
operative chemotherapy increased during the study period.
Survival outcomes among patients treated in routine clinical
practice are comparable to institution-based studies.
OP-I.24 PATIENTS WITH HEPATITIS B
PRESENT WITH MORE ADVANCED
LIVER CANCER THAN PATIENTS WITH
HEPATITIS C
J. L. Pasko1, A. C. Anderton1, C. Costantino1, S. L. Orloff1,
L. L. Wong2, W. E. Naugler3
1Oregon Health And Sciences University, Department Of
Surgery, Portland, OREGON; 2University Of Hawaii
Cancer Center And School Of Medicine, Department Of
Surgery, Honolulu, HI; 3Oregon Health And Sciences
University, Department Of Hepatology, Portland,
OREGON
Background: Well-described factors affecting the incidence
of Hepatocellular Carcinoma (HCC) include gender, age, and
etiology of liver disease. Factors that may affect the stage of
HCC at presentation are poorly understood. Stage at presen-
tation, however, largely dictates available treatments and ulti-
mately prognosis for patients.
Aims: Using a large cohort of patients with HCC, identify
elements that correlate with HCC stage at initial BCLC stage.
Methods: This is a two-institution retrospective review of
patients with pathologically or radiographically confirmed
HCC from January 1991–August 2014.
Results: There were 1134 patients (835 men and 299
women) with HCC in this study. MELD scores ranged from
6–38. Higher MELD scores correlated with higher stages of
HCC (p = .01). Screening was found to correlate with a lower
BCLC stage (p = .001). Additionally, patients with HBV pre-
sented at higher stages (p = 0.03) compared to patients with
HCV who presented at lower stages (p = .001). Thirty-three
percent of patients with HCV were screened, and 19% of
HBV patients were screened. There was no difference in
mean MELD score in HCV vs HBV patients. (10.8 vs 10.3,
p = 0.10) Mean tumor size for HCV was 4.4 cm compared to
6.7 cm in HBV (p = 0.001).
Conclusions: Despite similar MELD scores between
patients with HCV and HBV, patients with HBV infection
presented with higher stages of HCC and larger tumors. It is
unclear if this is biologically driven or is related to a screen-
ing disparity between the two groups.
OP-I.25 IMPACT OF POSTOPERATIVE
MORBIDITY AND LIVER FAILURE ON
SURVIVAL OF PATIENTS WITH
RESECTED COLORECTAL LIVER
METASTASES
H. S. Ribeiro, M. C. Marques, R. S. De Souza,
W. L. Da Costa, A. L. Diniz, A. L. De Godoy,
I. C. De Farias, H. C. Freitas, F. J. Coimbra
A.C. Camargo Cancer Center, Sao Paulo, Brasil
Liver resection has become the best chance of cure for
patients with colorectal liver metastases. However, studies
have shown that postoperative complications could compro-
mise long-term survival results. The aim of this study was to
determine the incidence and prognostic factors for postop-
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erative morbidity, including liver failure, and their impact on
long-term survival. Patients who underwent liver resection
for colorectal liver metastases between 1998 and 2012 were
analyzed. Any deviation from usual postoperative early
outcome was recorded as complications and stratified
according to the Clavien-Dindo classification. Three hundred
forty-six liver resections were performed in 285 patients.
Postoperative morbidity occurred in 57.8% of operations and
90-day mortality was 3.4%. Major complications (grade 3
and 4) occurred in 21.1% of hepatectomies. Twenty-three
(6.6%) patients had postoperative liver failure. After a
median follow-up period of 37.5 months, patients who had
major postoperative complications and/or postoperative liver
failure had statistically significant worse 3-year overall sur-
vival. In multivariate analyses, both factors were independent
predictors of survival (Major postoperative complications
HR = 2.1, p = 0.004, 95% CI 1.2–3.7; postoperative liver
failure HR = 1.9, p = 0.046, 95% IC 1.0–3.8). However,
these factors had no impact on disease free survival. These
findings may be explained by a decrease in life expectancy
observed in patients who experience life-threatening events.
Detailed clinical preoperative evaluation, careful surgical
techniques and meticulous postoperative care may improve
long-term survival results.
OP-I.26 GADOXETIC ACID (GA)
RELATIVE LIVER ENHANCEMENT
(RLE) ON PREOPERATIVE MAGNETIC
RESONANCE IMAGING (MRI) AS A
MARKER OF LIVER FUNCTION TO
PREDICT THE RISK OF
POST-HEPATECTOMY LIVER
FAILURE (PHLF)
A. Tremblay St-Germain1, A. Costa2, R. Smoot3,
K. Jhaveri2, S. Cleary1
1Department Of Surgery, Toronto General Hospital,
University Of Toronto, Toronto, ON; 2Joint Department Of
Medical Imaging, Toronto General Hospital, University Of
Toronto, Toronto, ON; 3Department Of Surgery, Mayo
Clinic, Rochester, MN
Preoperative liver function and future liver remnant (FLR)
are typically used to predict the risk of PHLF. The hepatic
physiologic reserve and ability to hypertrophy are difficult to
predict. We investigated the use of contrast-enhanced MRI
with GA as a marker for liver function and potential predictor
of PHLF. We retrospectively analyzed all consecutive
patients who underwent major liver resection (≥3 segments)
and preoperative MRI-GA at our institution between October
2010 and December 2013. Mean RLE was calculated based
on regions of interest drawn of the liver on the unenhanced
and hepatobiliary phases. The associations between mean
RLE and PHLF according to the 50-50 and ISGLS criterias
were tested with univariate and multivariate logistic regres-
sion analysis. 68 patients (44 men; median age 60.5 years)
fulfilled the inclusion criterias: 47 CRLM, 14 HCC, 2
intrahepatic cholangiocarcinoma, 2 NETLM and 3 benign
diseases. 1 patient had PHLF according to the 50-50 criteria
and 13 patients had PHLF according to the ISGLS criterias (4
grade A, 8 grade B, 1 grade C and death). Mean RLE corre-
lated with the presence and stage of fibrosis on histology
(p = 0,032 and p = 0,045). In logistic regression analysis,
mean RLE with a cut-off of 100%, in combination with FLR,
increased the ability to predict the presence of PHLF accord-
ing to the ISGLS criteria. However, it did not reach statistical
significance as an independent predictor. MRI-GA and mean
RLE, in addition to FLR, can improve risk assessment for
PHLF after major liver resection.
OP-I.27 THE LEARNING CURVE EFFECT
IN LAPAROSCOPIC LIVER RESECTION
V. Villani, F. Sabbatino, R. Torabi, D. L. Berger,
K. K. Tanabe, K. D. Lillemoe, C. R. Ferrone
Massachusetts General Hospital – Department Of Surgery,
Boston, MA
Background: The expansion of laparoscopic liver resection
(LLR) has been considerably slower compared to that of
other laparoscopic procedures. In this study we analyzed the
learning curve associated with LLR.
Method: Retrospective database analysis of consecutive
LLR performed between 3/07–6/14. Procedures were
divided in three chronological groups: A (03/07–05/11,
43 pts), B (05/11–05/13, 43 pts), C (05/13–06/14, 42 pts).
Results: The three groups were comparable for patients’
median age (57 yo; 59 yo; 59 yo), gender (25.6, 39.5, 45.2,%
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male), percentage of patients who had a resection for a
malignancy (86.0%, 83.7%, 65.6%), and median operative
time (182 min, 190 min, 197 min). Complex procedures
(defined as: trisegmentectomies, left hepatectomies, right
hepatectomies or central hepatectomies) increased signifi-
cantly over time (P = 0.007). One 90-day mortality occurred
in group A, while mortality in groups B and C was zero.
There was an improving trend in estimated blood loss (568.5,
563.9, 342.0 ml), in number of patients transfused (4, 3, 2
patients), conversion to open procedures (4, 2, 1 conver-
sions), number of complications (8, 3, 4 complications,
Clavien grade III or higher). Median length of stay was
significantly reduced in groups B and C (6.4 days, 3.8 days,
3.8 days; P = 0.006).
Conclusions: Similar to other surgical procedures, LLR is
subject to a learning curve. Despite an increase in surgical
complexity, after the first 43 procedures there was an
improvement in blood loss, rate of conversion, morbidity,
and length of stay.
OP-I.28 SAFETY AND EFFICACY OF A
NEW ARTICULATING BIPOLAR
ENERGY DEVICE FOR PARENCHYMAL
TRANSECTION IN LAPAROSCOPIC
LIVER RESECTION
C. Dural, M. Akyuz, E. Aksoy, P. Yazici, F. Aucejo,
C. Quintini, C. Miller, J. Fung, E. Berber
Cleveland Clinic, Cleveland, OH
Background: The aim of this study is to assess the safety
and efficacy of a new articulating vessel sealer (VS) for
laparoscopic liver resection (LLR).
Methods: A new 5 cm, bipolar VS was used in 28 LLRs
(group 1). A comparison was made to 28 patients who under-
went LLR (group 2) using other energy devices. T-test and
Chi square were used for statistics.
Results: Tumor type was malignant in 71% of patients in
group 1 and 89% of the patients in group 2 (p = 0.360).
Number and size of tumors, and resection type were similar
in both groups. In group 1, less number of adjunctive devices
(i.e. energy, clip appliers, staplers) were used (median 2)
versus group 2 (median 3, p = 0.032). Staplers were used in
28% (n = 8) of cases in group 1 and 54% (n = 15) in group 2,
with fewer number of cartridges fired in group 1, when used
(median 1.5 vs 4, respectively, p = 0.005). Parenchymal
transection time (28.2 ± 3.5 minutes vs 55.2 ± 4.1, respec-
tively, p < 0.001) and total operative time (200.1 ± 13.7 vs
242.7 ± 14.4, respectively, p = 0.036) were shorter for group
1. Morbidity was 11% (n = 3) in group 1 and 18% (n = 5) in
group 2 (p = NS). Intraoperative costs were an average of $
3000 less in group 1 versus group 2 (p = 0.0029).
Conclusion: This study demonstrates the safety and efficacy
of a new energy device for LLR. The data suggests a poten-
tial benefit of this device to reduce operative time and
decrease costs by facilitating parenchymal transection.
OP-I.30 TREATMENT OF RECURRENCE
AFTER RESECTION OF
HEPATOCELLULAR CARCINOMA
IN CIRRHOTIC LIVER
Z. Rong, Y. Collin, S. Turcotte, M. Dagenais,
R. Letourneau, M. Plasse, A. Roy, R. Lapointe,
F. Vandenbroucke-Menu
Centre Hospitalier De L’Universitaire Montreal (CHUM),
Montreal, QUEBEC
Background: High recurrence rates after liver resection for
hepatocellular carcinoma (HCC) remain problematic and no
consensus exists on the optimal management of recurrence.
Methods: A retrospective analysis was performed on cir-
rhotic patients with resected HCC in our center between
1992 and 2013. Survival and recurrence outcomes were
analyzed.
Results: Ninety-four patients with Child A (90 patients;
95.7%) or B (4 patients; 4.3%) cirrhosis were included.
There were 79 males with a mean age of 60.8 ± 11.2 years.
Major hepatectomy was performed in 43 patients (45.7%).
Median HCC size was 3.5 cm (0.8–16.0 cm) and 79 patients
(84.0%) had a single tumor. Forty-three patients (45.7%)
experienced recurrent disease, mostly intrahepatic (36
patients; 83.7%). Overall and disease-free survivals were
70.0% and 48.4% at 3 years, and 61.6% and 41.6% at 5 years.
Inferior overall and disease-free survivals were significantly
associated with positive margins (p = 0.005 and p < 0.001),
multiple tumors (p = 0.018 and p = 0.03), and multino-
dularity (p = 0.007 and p < 0.001). Age (<65 years;
p = 0.03), tumor size (<3 cm; p = 0.02) and lower T stage
(p = 0.02) were linked with longer overall survival. Invasion
of adjacent organs (p < 0.001) and major vascular structures
(p = 0.01) were associated with recurrence. Thirty-three
patients with recurrent HCC received treatment, which
included chemotherapy (13 patients), chemoembolization
(12), radiofrequency (8), alcoholization (3), repeat resection
(4), or transplantation (3). Overall survival was significantly
superior in patients with treated recurrence (p = 0.005).
Conclusions: Recurrence is frequent after HCC resection,
particularly in patients with invasion of adjacent organs or
vascular structures. However, satisfactory 5-year survival
rates are achievable in patients with treated recurrent disease.
OP-I.31 MULTIMODAL TREATMENT OF
UNRESECTABLE HEPATOCELLULAR
CARCINOMA TO ACHIEVE COMPLETE
RESPONSE RESULTS IN IMPROVED
SURVIVAL
P. Newell1,2,5, R. Uppal3, Y. Wu1, H. Hoen1,5, J. T. Thiesing4,
K. Sasadeusz4, M. Cassera1, R. Wolf1,2, P. Hansen1,2,
C. Hammill1,2
1Providence Cancer Center, Portland, OR; 2The Oregon
Clinic, Portland, OR; 3The Portland Clinic, Portland, OR;
4The Radiology Group, Portland, OR; 5Earle A. Chiles
Research Institute, Portland, OR
Introduction: With technological advances, questions arise
regarding how to best fit newer treatment modalities, such as
transarterial therapies, into the treatment algorithm for
patients with hepatocellular carcinoma (HCC).
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Methods: Between 2005–2011, 128 consecutive patients
initially treated with transarterial radioembolization or
chemoembolization using drug-eluting beads were identi-
fied. Response was graded retrospectively. Toxicity was
measured at 1,3, and 6 months after first and last treatments
by recording biochemical adverse events in bilirubin,
albumin, and INR.
Results: 53% of the patients were considered to have
advanced stage disease (BCLC stage C). 16% of patients had
an initial complete response, but with additional treatments,
this was increased to 36%. Patients with a complete response
as their best response to treatment had a median survival
(95% confidence interval) of 5.77 (2.58, the upper limit has
not yet been reached) years, significantly longer than those
whose best response was a partial response, 1.22 (0.84, 2.06)
years and those with stable disease as their best response,
0.34 (0.29, 0.67) years. Repeated treatments did not increase
the risk of toxicity.
Discussion: This retrospective review of patients treated for
intermediate and advanced stage HCC revealed a significant
survival advantage in patients who achieved a complete
response. We did not demonstrate superiority of one modal-
ity over the other, but did show that the two could be used
sequentially without accumulating significant toxicity. These
data support use of a multi-modality approach to intermedi-
ate and advanced stage HCC, combining liver-directed treat-
ments as necessary to achieve a complete response.
OP-I.32 HEPATIC RESECTION FOR
DISAPPEARING LIVER METASTASIS:
A COST-UTILITY ANALYSIS
G. Spolverato1, A. Vitale2, A. Ejaz1, D. Cosgrove1,
D. Cowzer1, U. Cillo2, T. M. Pawlik1
1Johns Hopkins Hospital, Baltimore, MARYLAND;
2Universita Di Padova, Chirurgia Epatobiliare E Trapianto
Epatico, Padova, PADOVA
Introduction: Data on cost-effectiveness and efficacy of
hepatic resection(HR) for colorectal liver metastasis that
disappear after systemic chemotherapy(sCT) are lacking. We
estimated the cost-effectiveness of HR plus 6 months of sCT
in case of recurrence(strategy A) relative to surveillance and
6 months of sCT in case of recurrence(strategy B) for
patients with colorectal disappearing liver metastasis(DLM).
Methods: Through a Markov model three base cases were
evaluated involving a 65 year-old patient with three lesions in
the right hemi-liver who underwent 6 months of sCT and
1)had DLM based on MRI; 2)had DLM based on CT scan;
3)had also hepatic artery infusion(HAI) with subsequent
DLM based on CT scan.
Results: The NHB of strategy A(HR) versus strategy
B(surveillance) was negative(-1.7 QALMs) for base case 1.
In contrast, the NHB of HR was positive in base case 2(5.4
QALMs); the NHB of HR was positive for base case 3, but
the effect was much more modest(0.15 QALMs). The ICER
of strategy A versus B was highest for base case 1($105,216/
QALY) and lowest for base case 2($-18,768/QALY); the
ICER for HR versus surveillance was intermediate for base
case 3($48,924/QALY). Sensitivity analyses demonstrated
that HR was cost effective when compared with surveillance
when the rate of complete pathological response after 6
months of sCT was estimated to be <60%.
Conclusion: Surveillance of DLM is an acceptable strategy
when the diagnosis of DLM is made through MRI. NHB and
ICER favor HR when the presence of DLM is determined by
CT scan alone.
OP-I.33 SIMULTANEOUS RESECTION OF
PRIMARY COLORECTAL CANCER AND
SYNCHRONOUS LIVER METASTASES:
A POPULATION-BASED STUDY
S. Nanji1,2, W. J. Mackillop2,3,4, X. Wei3, C. M. Booth2,3,4
1Department Of Surgery, Queen’s University, Kingston,
ON; 2Department Of Oncology, Queen’s University,
Kingston, ON; 3Department Of Public Health Sciences,
Queen’s University, Kingston, ON; 4Division Of Cancer
Care And Epidemiology, Queens University Cancer
Research Institute, Kingston, ON
Background: The role of combined resection of primary
colorectal cancer (CRC) and synchronous liver metastases
(LM) is gaining interest. Here we describe management and
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outcomes of patients in the general population managed with
simultaneous or staged resection of the primary tumor and
synchronous CRC LM.
Methods: All cases of CRC in Ontario who underwent
surgical resection of LM in 2002–2009 were identified using
the population-based Ontario Cancer Registry. Synchronous
disease was defined as having resection of CRC LM
within 12 weeks of surgery for the primary tumor. Pathology
reports were reviewed to identify extent of disease and
surgery.
Results: During 2002–2009, 1711 patients underwent resec-
tion of CRC LM; pathology reports were identified for 1252
cases. 283 patients had synchronous disease; 116 (41%)
patients had simultaneous resections and 167 (59%) had a
staged resection. For the simultaneous and the staged groups,
mean number of liver lesions resected was 1.7 and 2.3
(p < 0.001), mean size of the largest lesion was 3.1 and
4.7 cm (p < 0.001), major hepatic resection (≥3 Couinaud
segments) rate was 26% and 76% (p < 0.001) and the R1
resection margin rate was 10% and 8% (p = 0.46), respec-
tively. 30- and 90-day post-operative mortality rates for sim-
ultaneous and staged groups were 0.9% and 2.4% (p = 0.65)
and 3.5% and 4.2% (p = 1.00), respectively.
Conclusions: Simultaneous resection of synchronous CRC
LM is common in routine clinical practice. Compared to a
staged approach, patients undergoing simultaneous resec-
tions had fewer and smaller liver metastases, less aggressive
resections and comparable post-operative mortality.
OP-I.34 COMPARATIVE ANALYSIS OF
LAPAROSCOPIC RESECTIONS OF
POSTEROSUPERIOR SEGMENTS IN
SEMIPRONE POSITION VS.
LAPAROSCOPIC LEFT LATERAL
SECTIONECTOMY IN SUPINE POSITION.
DO WE NEED TO REDEFINE THE
DEFINITION OF A MAJOR
LAPAROSCOPIC LIVER RESECTION?
M. D’Hondt1, E. Yoshihara1, D. Devriendt1,
F. Vansteenkiste1, H. Pottel2
1Dept. Of Digestive And HPB Surgery, Groeninge Hospital,
Kortrijk, W-VL; 2Interdisciplinary Research Center,
Catholic University Leuven, Campus Kortrijk, Kortrijk,
W-VL
Introduction: The Louisville-statement defined laparo-
scopic resections of posterosuperior segments (LPSS) as
major hepatectomies. It has been shown that LPSS, are asso-
ciated with a good field of view,lower conversion rate and
less blood loss when performed in semiprone position. All
patients whom underwent LPSS at our center were posi-
tioned in semiprone since August 2011. The aims of this
study were to assess differences in perioperative outcomes
between laparoscopic left lateral sectionectomies (LLLS)
performed in supine position and LPSS in semiprone.
Methods: We reviewed a prospectively collected single-
center database of all liver resections performed between
August 2011 and August 2014. LLLS and LPSS were com-
pared with respect to demographics and perioperative
outcomes.
Results: Thirty nine patients underwent LLLS(n = 19) or
LPSS(n = 20). There were no differences in demographics
(table) or maximal tumor diameter (p = 0.7569). There were
no conversions. Pringle manoeuvre was not used in both
groups.There was no difference in peroperative central
venous pressure. Operative time in the LLLS group was 100
(60–160) min and 150 (100–270) min in the LPSS group
(p = 0.0037) with median intra-operative blood loss in the
LLLS group of 50(0–550) ml versus a larger 150(50–700) ml
(p = 0.0191) for patients receiving LPSS. No patients
required transfusion. Intraoperative and postoperative com-
plication rate was similar in both groups. Mortality rate was
nil in both groups. Median hospital stay was 6 days in both
groups (p = 0.6382).
Conclusion: LPSS in semiprone can be performed with
similar clinical outcomes as a minor laparoscopic liver resec-
tion except for longer operative time and larger intraoperative
blood loss without the need for transfusion.
OP-I.35 ASSOCIATING LIVER
PARTITION AND PORTAL VEIN
LIGATION IN STAGED HEPATECTOMY
(ALPPS) IN SCANDINAVIA. A
TRI-INSTITUTIONAL INTRODUCTORY
FEASIBILITY STUDY
B. I. Rosok1, E. Sparrelid2, B. Bjrnson3, B. A. Bjrnbeth1,
B. Isaksson2, L. Lundgren3, E. Pomianowska1,
T. Gasslander3, P. Sandstrm3
1Section For HPB Surgery, Oslo University Hospital, Oslo,
NONE; 2Department Of Surgery, Stockholm, NONE;
3Surgical Department,, Linkg, NONE
Introduction: ALPPS has been introduced as an alternative
to conventional portal vein embolization or – ligation (PVE/
PVL) in patients with technically resectable liver tumors but
insufficient future liver remnant. Initial experiences however,
indicated that the complication rate and perioperative mor-
tality following ALPPS exceeded that of PVE/PVL.
Materials and Methods: Thirty patients (19 males 11
females) were operated during a 5 month period at our three
institutions. Underlying diagnoses were colorectal liver
metastases (n = 23), Cholangiocarcinoma (n = 4), HCC
(n = 2) and Carolis syndrom The number of lesions varied
from 1–20. None of the patients had underlying liver disease.
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Results: All patients completed the 2-stage procedure at a
median of 8 days (7–15) following procedure 1. Twenty-three
patients had extended right hepatectomies, wheras the remain-
ing 7 had conventional right hemihepatectomies. Median
hospital stay after the second procedure was 9.5 days (2–50).
No perioperative mortality was observed. Complications
according to Clavien-Dindo grading was 9 grade 1, 9 grade 2,
4 grade 3A and 3 patient with a grade 3b complication.
Discussion/Conclusion: ALPPS may be an alternative to
PVE/PVL in some patients. An acceptable complication rate
can be obtained if certain selection criteria are met. Many
patients have early recurrences following ALPPS, and our
short and intermediate oncological results will be presented.
Randomized controlled trials are necessary to define what
patients may benefit from ALPPS. A multicentre Scandina-
vian trial, LIGRO (ClinicalTrials.gov NCT02215577) has
therefore been initiated and has been enrolling patients since
May 2014.
[Correction added on 2 March 2015, after online publication.
The abstract “OP-I.36 LIVER ABSCESS: A REVIEW OF
MANAGEMENT AND CLINICAL OUTCOMES AT
WESTERN HEALTH, AUSTRALIA” has been deleted.]
OP-I.37 FACTORS PREDICITNG
OUTCOMES IN NON-TRAUMATIC
EMERGENCY HEPATECTOMYA
NSQIP ANALYSIS
J. A. Parikh1, S. Anantha Sathyanarayana1, S. Bendix1,
M. J. Jacobs1, R. Kather2, I. S. Rubenfeld1
1St.John Providence And Providence Park Hospitals,
Southfield, MI; 2Henry Ford Hospital, Detroit, MI
Introduction: Although non-traumatic emergent hepatec-
tomies are rarely indicated, their burden to healthcare system
in terms of utilization of resources is likely to be high, though
has never been quantified.
Methods: Using the ACS-NSQIP participant use files
for 2005–2012, we identified hepatic resections by Current
Procedural Terminology (CPT) code and segregated all
non-traumatic hepatectomies into 2 groups: Emergent Hepa-
tectomy (EH) and Non-emergent Hepatectomy(NEH).
Preoperative, intraoperative and postoperative factors were
analyzed to identify predictors of complications and
mortality.
Results: Of the 13227 non-traumatic hepatectomies from
the NSQIP data, 137 emergency hepatectomies were identi-
fied. African Americans required significantly increased EH
(2.0% vs 0.92%, OR 2.2, p < 0.001). The most common
diagnosis for EH overall, was primary and secondary malig-
nant neoplasm of the liver (38%; n = 33). Preoperative and
perioperative transfusion requirements were higher in the EH
group compared to NEH (17.5% vs 0.49%, OR 42.5,
P < .001; and 52.7% vs 26.4%, OR 3.1, P < .001). Patients in
the EH group were significantly more likely to experience a
Clavien 4 complication (19.7% vs 7.2%, OR 3.2, p < .001).
Mortality rate was higher in the EH group compared to
NEH(8.8% vs 2.5%, OR 3.7, P < .001).A multivariate logis-
tic regression analysis revealed ASA score, ascites, and
emergent indication as poor outcome indicators. Surprisingly
age and length of operation were not significant factors.
(Table 1).
Conclusion: Emergent hepatectomy has a significantly
higher perioperative blood transfusion requirement, with
increased morbidity and mortality rate. ASA score, ascites,
and emergent indication as poor outcome indicators, while
age and length of operation were not significant factors.
OP-I.38 DETECTION OF INVISIBLE
LIVER TUMORS USING REAL-TIME
VIRTUAL SONOGRAPHY
A. Miyata, Y. Mise, T. Aoki, J. Kaneko, Y. Sakamoto,
K. Hasegawa, Y. Sugawara, N. Kokudo
The Univercity Of Tokyo Hospital, Tokyo, TOKYO
Introduction: Real-time virtual sonography is an innovative
imaging technology that synchronizes an intraoperative
ultrasonography (IOUS) with preoperative computed tomog-
raphy (CT). We validated the effectiveness of the navigation
system in 2 cases to locate liver tumors, which had been
found in preoperative images and were difficult to detect
using conventional intraoperative inspection.
Case 1: A 65-year-old man had a metastatic liver tumor
from renal cell carcinoma. Preoperative CT revealed that the
tumor was 6 mm in size, located in the deep segment 6.
Intraoperatively, the tumor was not detected using plain and
enhanced ultrasonography. Real-time virtual sonography
projected the CT image of the tumor on IOUS image, which
helped us to add mobilization of the liver. After mobilizing
the liver towards the tumor location, we could find and resect
the tumor using additional enhanced IOUS.
Case 2: A 58-year-old man had a 6 mm-hepatocellular car-
cinoma located in segment 4. He had a previous history of
left lateral sectionectomy for hepatocellular carcinoma. The
recurrent tumor located in the previous cut surface of the
liver was not found by conventional IOUS because of the
severe adhesion. We used real-time virtual sonography,
which navigated us to dissect the adhesion towards the tumor.
Conclusions: A novel navigation system using real-time
virtual sonography is helpful to locate small tumors that are
difficult to find using conventional intraoperative inspection.
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OP-I.39 THE NEED FOR
HEPATOPANCREATOBILIARY
SURGEONS: ARE THE COMMUNITY
HOSPITALS UNDERSERVED?
S. Anantha Sathyanarayana, S. Randhawa, P. Annigeri,
G. Marshall, E. Negussie, M. J. Jacobs, J. A. Parikh
St.John Providence And Providence Park Hospitals,
Southfield, MI
Introduction: Surgical educators have recently questioned
if too many Hepato-Pancreato-Biliary (HPB) surgeons are
being trained. While academic centers may be saturated,
many community hospitals may be underserved. Thus, we
sought to determine the need for an HPB surgeon at a tertiary
care community hospital.
Methods: All abdominal computed tomography (CT) scans
from February 2014 to May 2014 performed at a community
teaching hospital were reviewed and scans with pertinent
HPB pathology were isolated.
Results: A total of 389 CT scans having pertinent HPB
pathology were identified from 3500 scans, for which an
HPB surgeon consultation would be appropriate (Table 1).
Out of the 291 patients with liver specific pathology, 17
patients had hepatic cysts >4 cm in size, 76 had a solid mass.
Eighty three patients were found with pancreatic pathology,
out of which 17 patients had cystic lesions >1 cm, 21 of them
had a solid mass, 13 had non-specific main duct dilatation
and 9 had chronic pancreatitis. Fifteen patients had biliary
pathology including 11 with biliary ductal dilatation, one
choledochal cyst and one extrahepatic bile duct stricture. For
the 3 month study period, a total of 178 patients with signifi-
cant HPB pathology were identified and the projected
volume of patients will be over 700 for a period of 1 year that
would require an HPB surgeon consultation.
Conclusions: The national need for HPB surgeons should
be re-evaluated based on the workload at the community
hospital setting and cannot be based on saturation at the
academic hospitals.
OP-I.40 EVALUATING THE IMPACT OF
ADDING PERIOPERATIVE HOSPITALIST
CO-MANAGEMENT ON OUTCOMES
FOR PATIENTS UNDERGOING
PANCREATICODUODENECTOMY
M. Brown, P. M. Campbell, R. F. Wolf, W. C. Johnston,
M. A. Cassera, C. W. Hammill, P. H. Newell, P. D. Hansen
Providence Portland Medical Center, Cancer Center,
Portland, OREGON
Introduction: We hypothesize elderly patients, with multi-
ple comorbidities, undergoing high risk surgical procedures
will benefit from pre- and postoperative co-management by a
hospitalist who specializes in this field. We report clinical
outcomes for two cohorts of patients undergoing pancreati-
coduodenectomy (PD), pre and post introduction of a
perioperative hospitalist (POH) program.
Methods: Data was collected retrospectively on 89 con-
secutive patients undergoing PD between 2012 and 2014.
Analysis was performed on 40 patients prior and 49 patients
after the introduction of the POH program. Groups were
compared by chi-square and T-test.
Results: Results are summarized in the table below. 14
patients in the post-POH cohort were not seen by the POH
due to patient selection, distance and transportation issues.
Although the ASA was significantly higher in the post-POH
group, overall complication rates were similar. 30-day read-
missions were also significantly lower in the post-POH
group. There were 4 deaths observed in the post-POH group,
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4 (8.2%) versus 0 in the pre-POH group. Deaths were due to
amioderone related pulmonary fibrosis (1), cardiac arrest (1),
and severe multi-organ failure related to a leak(1) and a
postoperative bleed (1).
Conclusion: The introduction of a hospitalist who special-
izes in perioperative management of high-risk surgical
patients was associated with a decrease in 30-day readmis-
sions and a similar overall complication rate, even in the
setting of a higher mean ASA. There was a trend toward a
higher mortality rate in the post-POH cohort. More study is
required to understand the overall quality and financial
impact of POH co-management.
OP-I.41 PERSONALITY TRAITS
COMMON AMONG
HEPATO-PANCREATO-BILIARY
SURGEONS AND THEIR RELATIONSHIP
TO JOB SATISFACTION
S. N. Osayi1, L. Yu2, J. Drosdeck1, C. E. Ellison1,
M. Bloomston1, C. Schmidt1, M. Dillhoff1, S. Weber3,
P. Muscarella1
1Department Of Surgery, The Ohio State University Wexner
Medical Center, Columbus, OH; 2Center For Biostatistics,
The Ohio State University, Columbus, OH; 3Department Of
Surgery, University Of Wisconsin, Madison, WI
Background: Personality may influence career choice, and
can predict job satisfaction. The purpose of this study was to
evaluate the personality traits of hepato-pancreato-biliary
(HPB) surgeons and to determine whether they correlate with
job satisfaction.
Methods: A web-based survey of surgical members of the
AHPBA was conducted. Personality traits and job satisfac-
tion were assessed using the Big Five Inventory and the Brief
Index of Affective Job Satisfaction instrument.
Results: One hundred and thirty-six HPB surgeons com-
pleted the survey, 22% response rate (86.8% male, 70.7%
>40 years old, 85.3% completed fellowship training, 50%
>10 years in practice, and 76.5% academic practice). HPB
surgeons scored higher on extraversion and conscientious-
ness, and lower on neuroticism (p < 0.001) compared to a
normal population sample (n = 71,867). High extraversion
p = 0.02) and low neuroticism (p < 0.001) independently cor-
related with job satisfaction. Job satisfaction was higher
among females (p = 0.004). While 91.9% of respondents
indicated that they would choose the specialty again, only
53.7% would recommend it to their child/family. Those who
would choose the specialty again were less neurotic
(p = 0.039) and more satisfied with their job (p = 0.003).
Additionally, those who would recommend the specialty
were more agreeable (p = 0.001), more satisfied (p = 0.002),
have been in practice longer (p = 0.006), and were more
likely to choose the specialty again (p < 0.001).
Conclusion: Extraversion and neuroticism correlate with job
satisfaction among HPB surgeons. Furthermore, female HPB
surgeons appear to have higher levels of job satisfaction.
These findings may aid in the recruitment of HPB trainees and
may have implications for job performance and patient care.
OP-I.42 IMPACT OF FOCUSED NURSING
EDUCATION CURRICULUM IN THE
CARE OF HEPATO-PANCREATO-
BILIARY (HPB) SURGICAL PATIENTS
J. Drummond, C. Aviles, A. Cochran, E. Baker,
R. Seshadri, J. Martinie, D. Iannitti, R. Swan
Carolinas Healthcare System, Charlotte, NC
Nurses provide point of contact care for HPB surgery
patients. To improve patient education, nurse-physician com-
munication, and nursing comfort with complex HPB patient
care, we offered a six hour nursing targeted, educational
course, to all nurses from inpatient units at a large, tertiary
care hospital. Topics included anatomy, pathology, surgical
procedures, nutrition, and pre/post-operative care of the HPB
surgical patient. Two weeks prior to the course, a 30 question
pre-test was distributed to all participants: 20 questions
regarding HPB disease processes, 4 regarding the partici-
pants’ background, and 6 describing comfort level, physician
communication, and experience caring for HPB patients. The
same test was given to participants following the course and
scores were compared. Descriptive statistics were performed,
survey results tallied. 59 nurses participated in the course: 50
completed the pre-test and 25 completed the post-test. 50%
of respondents reported nursing experience of less than 5
years. 68% reported working with HPB surgery patients over
half of their shifts. Average pre-test score was 11.1 (55.6%)
and post-test was 12.5 (62.5%), an increase of 13.5%
(p < 0.01). Nursing confidence, comfort, and communication
in the care of HPB surgery patients increased by 37.1%
(p < 0.01). The percentage who felt completely confident in
answering patient questions regarding HPB diseases more
than doubled (38.9% to 84.1%). Our focused HPB nursing
core curriculum course was associated with improved under-
standing of HPB anatomy and disease processes and
increased nursing confidence in caring for HPB surgical
patients. We hope this will translate to improved patient care
and nursing-physician communication.
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OP-I.43 OPEN DATA FOSTERS QUALITY
OUTCOMES FOR HPB SURGERY:
RESULT OF 1625 PANCREATIC AND
HEPATIC RESECTION
C. K. Chang, S. H. TEH, P. Fuchshuber, J. S. Choi,
P. D. Peng, B. L. Bolinger, C. E. Binkley, R. M. Ramirez,
G. B. Kazantsev, A. L. Spitzer, K. Kojouri, E. E. Rosas,
M. M. Mortenson, C. A. Perez, M. A. Schlieman
Kaiser Permanente Northern California
Hepatico-Biliary-Pancreas Collaborative, Walnut Creek,
CA
Introduction: Healthcare economics is driving hospital to
deliver improved “pay for performance” for all surgical pro-
grams. Much of the data regarding efficiency and perfor-
mance is not actionable on an individual surgeon level as it is
kept mostly anonymous. We hypothesize that the develop-
ment of the Center of Excellence initiative for HPB surgery
within KP integrated health care system which comprised of
21 medical centers, can improve surgical outcome by firstly
improve individual surgeon performance.
Methods: All HPB cases from 2008 to 2014 were retrospec-
tively analyzed. Three-time periods were chosen, and data
were given to all HBP surgeons. The first set of data served as
a baseline to provide transparency of operative time (OR) and
length of stay (LOS). The second set of data was prospective
obtained during the initiation of program development The
third set of data showed the result of the implementation of
such program including a bi-weekly conference to discuss
multifaceted best practices.
Results: See Graph
Conclusion: Transparency of surgical data allows surgeons
to self-identify potential surgical outliers among their peers.A
continuous open discussion of “best practice” in terms of
detail surgical technique, intra-operative management and
post-operative allows a gradual transition of “coaching” away
from their personal preference. A critical review of data and
discussion of best practice allows for systematic change in
efficient surgical technique as well as discharge criteria.
OP-I.44 DUODENAL NEUROENDOCRINE
TUMORS – LOCATION MATTERS
M. R. Sheikh, H. Osman, S. Cheek, S. Hunter,
D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Objective: Duodenal neuroendocrine tumors are rare. His-
torically, when feasible a less aggressive surgical approach is
always considered to treat these tumors. The aim of this study
was to identify factors associated with necessity for more
aggressive surgical procedures.
Method: All patients who underwent surgery for duodenal
neuroendocrine tumor between September 2005 and June
2014 have been identified retrospectively in our database.
Data collected included clinical presentation, operative find-
ings and histopathological data.
Results: 18 patients were identified that underwent surgical
management for duodenal endocrine tumors. This included 2
patient with transduodenal excision (11%), 2 patients with
duodenal resection (11%), 6 patients had antrectomy (33%)
and 8 underwent pancreaticoduodenectomy (44%). On analy-
sis, peri-ampullary location was the most common site of
duodenal endocrine tumors (n = 9, 50%). 77% (n = 7) of
peri-ampullary lesions led to pancreaticoduodenectomy. The
odds of having a pancreaticoduodenectomy is 10 times higher
when the lesion is in peri-ampullary location. 6 patients had
positive lymph nodes. The odds of having a positive lymph
node are almost 9 times higher when the lesion is in ampulla.
83% (n = 5) of tumors with positive lymph nodes were greater
than T1 stage. The odds of having positive lymph node is 3
times higher when lesion is greater than T1.
Conclusions: Ampullary location of neuroendocrine tumor
in duodenum is associated with higher odds of lymph node
positivity and need for treatment with more extensive pro-
cedures like pancreaticoduodenectomy.
OP-I.45 EARLY POST-OPERATIVE
HYPOPHOSPHATEMIA AS A NOVEL
PREDICTOR OF ANASTOMOTIC
FAILURE AFTER PANCREATIC
RESECTION: A RISK-PREDICTION TOOL
E. Sadot, L. Roach, C. A. McIntyre, P. J. Allen,
A. A. Eaton, M. I. D’Angelica, R. P. DeMatteo,
T. P. Kingham, Y. Fong, W. R. Jarnagin
Memorial Sloan Kettering Cancer Center, New York,
NEW YORK
Introduction: Leak-related complications (LRC) remain
serious potential sequela of pancreatic resection. Current
LRC risk assessment is inadequate and rarely affects man-
agement algorithms. Hypophosphatemia appears to correlate
with infective complications after some abdominal
operations. This study evaluates early post-pancreatectomy
hypophosphatemia as a predictor of LRC.
Methods: Consecutive patients who underwent pancreati-
coduodenectomy or distal pancreatectomy were analyzed.
LRC were defined as pancreatic leak, fistula, or abscess; only
grade 2 or higher LRC were recorded. Postoperative serum
phosphate levels and other recognized LRC risk factors (duct
diameter, soft pancreatic parenchyma, high-risk pathology,
excessive blood loss, procedure type, and preoperative
chemotherapy) were analyzed. Factors significant on multi-
variate analysis were used to construct an LRC risk prediction
model.
Results: From 2011 through 2012, 465 patients were
included with a median age of 66 years. LRC (grade >2) were
recorded for 85 patients (18%). Univariate analysis identified
the following predictors of LRC: hypophosphatemia on post-
operative day 3 (p = 0.006), small duct diameter (p = 0.007),
soft gland consistency (p = 0.002), and intra-operative
blood loss >400 cc (p = 0.01). Hypophosphatemia on post-
operative day 3(OR = 2.2, CI: 1.1–4.5), soft gland
consistency(OR = 3.1, CI: 1.7–6), and intra-operative blood
loss >400 cc(OR = 2.3, CI: 1.3–4) remained significant on
multivariate analysis and were used to construct an LRC risk
prediction tool, which had a negative predictive value of 93%
and a c-index of 0.68(Table 1).
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Conclusions: Early post-operative hypophosphatemia is an
independent predictor of LRC. A simple LRC risk prediction
tool that includes this variable accurately identified low-risk
patients and may help identify those most likely to benefit
from enhanced postoperative recovery pathways.
OP-I.46 SURVIVAL FOLLOWING
PANCREATICODUODENECTOMY
FOR STAGE 1A PANCREATIC
ADENOCARCINOMA IS NOT IMPROVED
BY MULTIMODALITY TREATMENT
K. T. Ostapoff, P. Thirunavukarasu, B. W. Kuvshinoff,
S. J. Nurkin, S. N. Hochwald
Roswell Park Cancer Institute, Buffalo, NY
Introduction: Pancreaticoduodenectomy is an integral part
of pancreatic adenocarcinoma treatment. NCCN guidelines
recommend patients undergo multimodality therapy, but few
studies validate its significance in early stage patients.
Methods: Using NCDB from 1998–2006, patients who
underwent a pancreaticoduodenectomy were identified.
Patients with invasive histology and stage 1 disease were
included. X2 test was used for categorical variables. Median
survival was estimated using Kaplan-Meier method with log-
rank comparison and Cox regression.
Results: Over 8 years, 2,801 patients were identified.
Median overall survival for Stage 1A (n = 1047) and Stage
1B (n = 1776) was 31.8 and 23.2 months with a median
overall follow-up of 23.7 months (0–172.9). Stage 1B
patients were more likely to have higher grade tumors
(p = 0.002), receive chemotherapy (p = 0.007) or radiation
(p = 0.002) and have positive margins (p < 0.0001). There
were no differences between groups with respect to lymph
node yield (LN) or type of treatment facility. For both stages,
chemotherapy, radiation, LN yield ≥17 nodes, age <70,
tumor grade and facility type were associated with an
improved overall survival on univariate analysis. However on
multivariate analysis, for Stage 1A patients only LN yield
≥17 was independently predictive of survival while chemo-
therapy, radiation, facility type, age and sex had no impact on
survival. For patients with Stage 1B, chemotherapy, age <70
and LN harvest ≥17 were associated with an improved
overall survival on multivariate analysis.
Conclusion: Despite guidelines recommending multi-
modality treatment for pancreatic adenocarcinoma, there is no
improvement in survival for patients with Stage 1A disease. A
surgery only approach should be considered for these patients.
FRIDAY, MARCH 13, 2015,
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COCKTAIL VIDEO
PRESENTATION
VC.01 TOTAL LAPAROSCOPIC
CENTRAL PANCREATECTOMY WITH
PANCREATIGOGASTROSTOMY FOR
HIGH RISK CYSTIC NEOPLASM
L. Schwarz, J. B. Fleming, M. H. Katz, J. E. Lee,
T. A. Aloia, J. Vauthey, C. H. Conrad
UT MD Anderson Cancer Center, Department Of Surgical
Oncology, Houston, TEXAS
Background: Organ-sparing pancreatic resection is impor-
tant in prophylactic surgery for cystic neoplasms. There is
controversy regarding the optimal surgical approach for pan-
creatic lesions in the neck or proximal body of the pancreas.
Central compared to distal pancreatectomy is technically
more challenging but preserves more functional pancreatic
tissue. Due to the prophylactic nature of the surgery and long
survival of patients with benign and borderline malignant
lesions, surgeons need to stratify greater importance to sur-
gical morbidity and sparing pancreatic parenchyma.
Patient: The patient is a 59-year-old active woman with a
symptomatic cystic neoplasm of the pancreas exhibiting high
risk imaging features. The cyst of 2.2 × 1.8 cm in the body of
the pancreas was impinging on the portal venous confluence.
Technique: The patient was positioned in the French Posi-
tion, the lesser sac was opened and the pancreatic body
exposed. A retropancreatic tunnel was created with staple
division of the neck. The body was mobilized off the
portal vein and splenic vessels transected. A retrogastric
pancreaticogastrostomy was sewn through an anterior
gastrotomy. The stent was delivered past the pylorus to
decrease pancreatic enzymatic activation.
Conclusion: Laparoscopic ultrasound helps in defining cyst
borders and minimal blood loss optimizes visualization
during the dissection. A minimally invasive pancreati-
cogastrostomy created through an anterior gastrotomy is
technically feasible and safe. This approach can minimize the
morbidity of prophylactic pancreatic surgery for patients with
cystic neoplasms. Nevertheless, it should not compromise
safety, oncologic completeness or an organ-sparing approach.
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